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ABSTRACT 
Background: Availability of comprehensive family planning services is fundamental in improving 
and ensuring women’s right to life and health. An estimated 222 million women have an unmet need 
for contraception, and 43.8 million pregnancies are terminated each year, of which 21.6 million are 
considered to be unsafe and one of the main contributors to maternal mortality and morbidity. Medical 
abortion using misoprostol alone, or preferably the combined regimen of mifepristone and 
misoprostol, is the medical development that could turn out to be the most important in the goal of 
reducing maternal mortality worldwide. Modern equipment and training cannot be provided where 
abortion is illegal. Thus, a medical method, administered by women themselves is a promising way to 
modernise and make abortion safe and accessible. Medical priming prior to vacuum aspiration has 
been proven to reduce the rate of complications, and should be standard care. Information on dosage 
and priming interval is crucial for safety and effectiveness.  
The effectiveness of long-acting reversible contraception (LARC) such as intrauterine contraception 
(IUC) is superior to short-acting contraception, the difference being most pronounced in young 
women. Furthermore, women, who have an IUC inserted post abortion, are less likely to have a repeat 
unwanted pregnancy and abortion. Therefore efforts are needed to facilitate IUC use in these groups. 
Methods and Results:  
Study I: Nulliparous women requesting a Cu-IUD were recruited (n=80), and randomised to priming 
with misoprostol and diclofenac, or to only diclofenac one hour prior to IUC insertion. Misoprostol 
was shown to facilitate insertion of IUC in nulliparous women, and to decrease the rate of difficult and 
failed insertions. Priming with misoprostol did not reduce pain associated with the IUC placement. 
Study II: Lactating mothers undergoing medical abortion were recruited and samples of breast-milk 
collected during the first seven days after mifepristone treatment (n=12). Levels of mifepristone in 
breast-milk were low, with milk-plasma levels of 0.042:1 or less and calculated RID of 0.5 %.  
Study III: Healthy women requesting medical first trimester abortion and IUC post abortion were 
recruited (n=129), and randomized to early insertion during the first week, or to routine, delayed 
insertion. There was no increased rate of expulsions, PID or bleeding complications after early IUC 
insertion.  
Study IV: Healthy women undergoing vacuum aspiration were recruited (n=184), and randomised to 
priming with misoprostol sublingual (SL) or vaginal (PV), one or three hours before surgery. SL 
misoprostol was proven to be as effective after one hour as after three hours priming interval in regard 
to baseline cervical dilatation, peak force and cumulative force. SL misoprostol was more effective 
compared with PV misoprostol after one hour priming. Fewer women started bleeding prior to 
surgical intervention when priming interval was one hour.  
Conclusion: SL misoprostol reduces the cervical resistance after one hour priming interval, and can 
be used to facilitate insertion of an IUC to reduce difficult or failed insertions. Priming with SL 
misoprostol prior to vacuum aspiration is as effective after one hour as after three hours, and fewer 
women start bleeding before surgery. If PV misoprostol is used, the priming interval should remain at 
three hours. Medical abortion can be the method of choice for nursing mothers, and breastfeeding can 
be safely continued in an uninterrupted manner. After first trimester medical abortion, early IUC 
insertion is safe with no increased risk of expulsion or complications, and should therefore be offered 
as a routine, to ensure rapid initiation of highly effective contraception. 
 LIST OF SCIENTIFIC PAPERS 
 
I. 
Ingrid Sääv, Annette Aronsson, Lena Marions, Olof Stephansson and Kristina 
Gemzell-Danielsson 
Cervical priming with sublingual misoprostol prior to insertion of an 
intrauterine device in nulliparous women:a randomized controlled trial 
Human Reproduction 2007;22: 2647–2652 
 
II. 
Ingrid Sääv, Christian Fiala, Jonna M Hämäläinen, Oskari Heikinheimo and 
Kristina Gemzell-Danielsson 
Medical abortion in lactating women – low levels of mifepristone in 
breast milk 
Acta Obstetricia et Gynecologica. 2010; 89: 618–622 
 
 
III. 
Ingrid Sääv, Olof Stephansson, and Kristina Gemzell-Danielsson 
Early versus Delayed Insertion of Intrauterine Contraception after 
Medical Abortion - A Randomized Controlled Trial 
PLoS ONE 7(11): e48948. doi:10.1371/journal.pone.0048948 
 
 
IV. 
Ingrid Sääv, Helena Kopp Kallner, Christian Fiala, Kristina Gemzell-
Danielsson 
Sublingual versus vaginal misoprostol for cervical dilatation 1 or 3 hours 
prior to surgical abortion. A randomised, controlled, double-blinded 
trial. 
Manuscript  
 
  
CONTENTS 
1 Introduction ..................................................................................................................... 1 
1.1 Worldwide perspective .......................................................................................... 1 
1.2 Medical abortion .................................................................................................... 4 
1.3 Surgical abortion.................................................................................................... 7 
1.4 Misoprostol pharmacokinetics .............................................................................. 8 
1.5 Indications for misoprostol (other than medical abortion) ................................... 9 
1.5.1 Cervical priming in pregnant and non-pregnant women. ...................... 10 
1.5.2 Medical treatment of incomplete abortion and missed abortion............ 10 
1.5.3 Medical second trimester abortion and induction of labour after 
intrauterine foetal death during second and third trimester ................... 11 
1.5.4 Labour induction ..................................................................................... 11 
1.5.5 Prevention and treatment of postpartum haemorrhage .......................... 12 
1.6 Mifepristone pharmacokinetics ........................................................................... 14 
1.7 Intrauterine contraception ................................................................................... 15 
1.8 Postabortion contraception .................................................................................. 16 
2 Aims of the study .......................................................................................................... 17 
3 material and methods .................................................................................................... 19 
3.1.1 Study I...................................................................................................... 19 
3.1.2 Study II .................................................................................................... 20 
3.1.3 Study III ................................................................................................... 21 
3.1.4 Study IV ................................................................................................... 22 
3.2 Statistics ............................................................................................................... 23 
4 Results ............................................................................................................................ 24 
4.1.1 Misoprostol for cervical priming (study I and IV) ................................. 24 
4.1.2 Levels of mifepristone in human breast milk from women 
undergoing medical abortion (study II) .................................................. 26 
4.1.3 IUD and post-abortion contraception (study I and III) .......................... 26 
5 Discussion ...................................................................................................................... 28 
5.1 General aspects .................................................................................................... 28 
5.2 Misoprostol for cervical priming ........................................................................ 28 
5.3 Mifepristone and misoprostol in breast milk ...................................................... 30 
5.3.1 Misoprostol .............................................................................................. 30 
5.3.2 Mifepristone ............................................................................................ 31 
5.4 IUC and post abortion contraception (Study I and III). ..................................... 31 
6 Conclusions ................................................................................................................... 34 
6.1.1 Misoprostol for cervical priming in (Study I and IV) ............................ 34 
6.1.2 Levels of mifepristone in human breast milk in women 
undergoing medical abortion (study II) .................................................. 34 
6.1.3 IUC and post abortion contraception (Study I and III) .......................... 34 
6.2 Clinical recommendations ................................................................................... 36 
6.3 Possible areas for future research ........................................................................ 37 
7 Film recommendations .................................................................................................. 38 
8 Acknowledgements ....................................................................................................... 39 
9 References ..................................................................................................................... 43 
 
  
 
LIST OF ABBREVIATIONS 
 
 
ACTH 
Cu-IUD 
D&E 
FIGO 
IUB 
IUC 
 
 
Adrenocorticotropic hormone 
Copper coated intrauterine device 
Dilatation and evacuation 
International Federation of Gynecology and Obstetrics 
Intrauterine ball 
Intrauterine contraception 
IUD 
IUFD 
IUS 
LARC 
LNG-IUS 
MVA  
NSAID 
PID 
PO 
PV 
Intrauterine device 
Intrauterine foetal death 
Intrauterine system 
Long-acting reversible contraception 
Levonorgestrel-releasing intrauterine system 
Manual vacuum aspiration 
Non steroidal anti-inflammatory drugs 
Pelvic inflammatory disease 
Per oral 
Per vagina 
RCT 
RU 486 
SL 
UK 
Randimised controlled trialEnter the explanation 
Mifepristone 
Sub lingual 
United Kingdom 
WHO World Health Organisation 
 
  1 
1 INTRODUCTION 
 
1.1 WORLDWIDE PERSPECTIVE 
Availability of family planning services is a fundamental part in improving and ensuring 
women’s right to life and health. When improving women’s health and influence on fertility 
control, the general health in the society improves with a significant impact on health 
economics. This also includes the reduction of under-five child mortality (Cleland 2006). 
Increasingly, women’s rights to contraception and abortion services are being recognized as 
human rights issues (Mbizvo et al 2013).  
The availability of modern contraception reduces, but can never eliminate the need for 
abortion. When women have access to safe abortion services and safe contraceptive methods, 
the abortion rate declines (Bongaarts and Westhoff 2000). An estimated 40% of pregnancies 
are unplanned after non-use of contraception, ineffective contraception or method failure. If 
the need for contraception could be fully met, it is estimated that 75% of unsafe abortions 
could be prevented. Currently more than 222 million women have an unmet need for 
contraception (Mbizvo et al 2013).  When abortion services are legal and performed by safe 
modern methods, morbidity and mortality is minimal (Ipas (2014) Clinical Updates in 
Reproductive health). 
Increasing the knowledge of bodily functions and contraceptive methods as well as increasing 
access to modern contraception can reduce the number of unplanned pregnancies.  Improving 
literacy and infrastructure will improve women’s knowledge and access to modern 
contraceptive methods, but will also enable early diagnosis of pregnancy, reducing the time 
span from confirmation of unwanted pregnancy to abortion, reducing the proportion of 
abortion being done as late abortions, and increasing access to safe abortion methods.  All 
this will in different ways improve women’s health by reducing the total number of abortions 
and the mortality and morbidity per abortion.  
Worldwide, it is estimated that 43.8 million pregnancies are terminated each year, of which 
21.6 million are considered to be unsafe (Sedgh G et al 2012, Shah I and Åhman E 2010, 
WHO Safe abortion: technical and policy guidance for health systems 2012). WHO defines 
an unsafe abortion as a procedure for terminating a pregnancy that is performed by an 
individual lacking the necessary skills, or in an environment that does not conform to 
minimal medical standard, or both (Bull World Health Organ 2014).  Unsafe abortions have 
been estimated to contribute to 13% of maternal mortality, but in some countries where 
abortion is illegal but where infrastructure and emergency obstetric care is of good standard, 
the proportion can be as high as 49% (WHO Unsafe abortion incidence and mortality 2012, 
Khan KS et al 2006).  Women of all reproductive ages are at risk when abortion care is sub-
standard, but the women who actually die, are more often younger, unmarried and have 
abortions later than 14 gestational weeks, illustrating the vulnerability of this group 
(Dragoman et al 2014). In some settings, contraceptives are also not available for single 
unmarried women.  When abortion is restricted, more often abortion care uses old-fashioned 
methods, such as dilatation and sharp curettage, known to cause substantially more 
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complications than MVA (manual vacuum aspiration) or medical abortion (Dragoman et al 
2014).   
 
 
Worldwide, it is estimated that 43.8 million pregnancies are terminated each year, of which 
21.6 million are considered to be unsafe (Sedgh G et al 2012, Shah I and Åhman E 2009, 
WHO Safe abortion: technical and policy guidance for health systems 2012). WHO defines 
an unsafe abortion as a procedure for terminating a pregnancy that is performed by an 
individual lacking the necessary skills, or in an environment that does not conform to 
minimal medical standard, or both (Bull World Health Organ 2014).  Unsafe abortions have 
been estimated to contribute to 13% of maternal mortality, but in some countries where 
abortion is illegal but where infrastructure and emergency obstetric care is of good standard, 
the proportion can be as high as 49% (WHO Unsafe abortion incidence and mortality 2012, 
Khan KS et al 2006).  Women of all reproductive ages are at risk when abortion care is sub-
standard, but the women who actually die, are more often younger, unmarried and have 
abortions later than 14 gestational weeks, illustrating the vulnerability of this group 
(Dragoman et al 2014). In some settings, contraceptives are also not available for single 
unmarried women.  When abortion is restricted, more often abortion care uses old-fashioned 
methods, such as dilatation and sharp curettage, known to cause substantially more 
complications than MVA (manual vacuum aspiration) or medical abortion (Dragoman et al 
2014).   
Several studies illustrate the connection between maternal mortality and liberal abortion laws. 
The most illustrative examples are the increased maternal mortality rates in Romania 
following the restrictive laws between 1966 and 1988, after which the rate of maternal 
mortality declined in complete harmony with the rate of illegal unsafe abortion (Stephenson P 
et al 1992). In South Africa maternal mortality from unsafe abortion declined by 91% after 
legalization of abortion in 1993 (Jewkes R et al 2005). More recent examples of decline in 
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maternal mortality after legalizing abortion can be found in Mexico City (van Dijk et al 2012) 
and Nepal (Henderson JT et al 2013).  
Modern equipment and training cannot be provided where abortion is illegal. Thus, a medical 
method, administered by the women themselves is a promising way to modernise and make 
abortion safe outside the law. In spite of restrictive abortion laws, use of misoprostol has been 
shown to correlate with dramatic decreases in observed complications from unsafe abortion, 
with an estimated 45% reduction of maternal mortality if 60% of the abortions are 
misoprostol-induced (Miller et al 2005, Briozzo et al 2006, Harper et al 2007). In Brazil, 
despite restrictive abortion laws, self-use of misoprostol has been shown to be associated with 
significant reductions of abortion related complications such as infections and excessive 
bleeding post abortion (Costa and Vessay1993) Most of the decline occurred in the years 
1992-1997, during which years misoprostol was approved and became available to women 
(Guedes et al 2000,Singh et al 2006).  In 2005, WHO listed mifepristone and misoprostol as 
essential medicines.  
Indeed, medical abortion using misoprostol alone, or preferably mifepristone and 
misoprostol, is the medical development that could turn out to be the most important one in 
the goal of reducing maternal mortality worldwide. 
 
 
 4 
 
 
 
1.2 MEDICAL ABORTION 
Primary prostaglandins have been used for termination of pregnancy since 1969 (Roth-
Brandel U et al 1970).Various routes of administration were used; intravenously, 
intramuscular, vaginally, intraamniotically and extra-amniotically.  Modern development of 
medical abortion started in the 1970s with prostaglandin injections intra-amniotically in 
second trimester abortion (Bygdeman and Wiqvist 1974). Also in the 1970s , a vaginal 
application of natural prostaglandin was developed, but this had a short duration with half-
lives in the circulation of less than a minute and required high and repeated doses (Lundström 
et al 1977). These high doses also caused a high rate of side-effects and pain. After the 
development of the synthetic antiprogesterone mifepristone (RU 486) there was a 
breakthrough for non-surgical methods to terminate early pregnancy. Mifepristone was found 
to be insufficiently effective for causing complete abortion on its own with only a 60 % 
success rate (Herrman et al 1982, Kovacs et al 1984, Baulieu 1989). Of major importance 
was the discovery that mifepristone could sensitise the myometrium to endogenous and 
exogenous prostaglandins. By combining mifepristone and a prostaglandin analogue it was 
possible to increase the uterine response to prostaglandin and thus reduce the doses of 
prostaglandin needed to induce abortion. In this way the total dose of the prostaglandin 
analogue could be five times lower, thus reducing the side-effects, with an increased rate of 
complete abortions to 94% (Bygdeman and Swahn 1985, Swahn and Bygdeman 1988). In 
1994 medical abortion was also approved for second trimester termination of pregnancy. 
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Medical abortion using mifepristone followed by a prostaglandin analogue was licensed by 
Exelgyn (Paris, France) and first approved for use up to 49 gestational days (7+0 weeks) in 
France in 1988. The initial approval included the use of sulprostone prostaglandin analogue, 
administered intramuscularly which was associated with severe cardiovascular side-effects. 
Later on the prostaglandin of choice for the French (European) approval became misoprostol. 
In collaboration with WHO, medical abortion with a vaginally administered prostaglandin 
analogue was developed for use up to 63 days of gestation (9+0 weeks), and approved in UK 
and Sweden in 1991-1992. The use of gemeprost has gradually been replaced by misoprostol.  
Today, medical abortion is one of the safest procedures in medical practice, with minimal 
morbidity and mortality risks (ipas (2014) Clinical Updates in Reproductive health). The 
recommended most effective protocol today with a success rate of 95-98% up to 9 weeks 
gestation is 200 mg of mifepristone followed 24 to 48 hours later by 800µg misoprostol 
vaginally or sublingually (Ashok et al 1998, Schaff et al 2000, Bartley et al 2001,  WHO 
Clinical practice handbook for Safe abortion 2014). The risk of ongoing pregnancy is 0.5%, 
and the risk of incomplete abortion with need of extra doses of misoprostol or surgical 
intervention is around 3% (Goldstone et al 2012, Cleland et al 2013). Risks of morbidity or 
death are minimal – with the rate of serious complications of 0.16% and death rate of 0.4 per 
100.000 medical abortion procedures, and it is equally safe for young and nulliparous women 
(Cleland at al 2013, Goldstone et al 2012, Niinimäki et al 2011) Using this regimen, it is even 
more effective than surgical abortion in terms of inducing complete abortion during very 
early pregnancy (RCOG 2004). In most countries in Europe the rate of medical abortion 
compared with surgical interventions has increased, and in some countries now exceeds 90 % 
(www.socialstyrelsen.se, www.socialstyrelsen.se/statistik/statistikdatabas/abort, 
Heikinheimo, personal communication 2014, http://urn.fi/URN:NBN:fi-fe201303202579), 
and this coincides with a higher proportion of very early abortions.  
Uterine contractility after prostaglandin without and with pretreatment of 
mifepristone (Bygdeman and Swahn 1985, Bygdeman personal communication 2014) 
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Andel aborter före utgången av 9:e graviditetsveckan utförd med medicinsk 
eller kirurgisk metod, 1993–2011 (www.socialstyrelsen.se) 
 
 
 
Andel aborter efter graviditetslängd 1983–2011 (www.socialstyrelsen.se) 
 
 
hours (www.misoprostol.org, WHO clinical practice handbook for safe abortions 2014). This 
regimen is less effective with a success rate of 85-90 % up to 12 weeks gestation and carries a 
higher rate of side-effects due to the higher doses needed of prostaglandins (WHO Safe 
abortion: technical and policy guidance for health systems 2012, von Hertzen et al 2007, 
Kulier R Complication rate is substantially higher after second-trimester abortion compared 
with early first trimester abortion. Also, the proportion of serious complications and maternal 
death are higher after second trimester abortion. Among the severe complications, requiring 
advanced medical care, are haemorrhage, cervical tearing, uterine perforation, endometritis, 
septic abortion, bowel injury and abdominal abscesses, and those are comparably more often 
associated with surgical D&E compared with medical second trimester abortion. The rate of 
serious complications (requiring surgery or blood transfusion) after medical second trimester 
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abortion is less than 1 %, and the overall rate of uterine rupture 0.08%, with a rate of 0.28% 
in women with previous caesarean section (Goyal  2009). 
In countries where access to abortion is limited and mifepristone is not available, there is a 
possibility to perform a safe self-administrated abortion using misoprostol alone. 
Recommended protocol is three doses of four tablets misoprostol sublingually every three 
2011). 
Recent development regarding medical abortion has focused on simplifying the treatment 
procedure to increase access and acceptability including safety of home-use and self-
determination of complete abortion (Kopp-Kallner et al 2012, Oppegaard et al 2014). 
Although this has many advantages for simplifying the process and increasing access, it may 
also have an implication  on the choice of contraception.  
 
1.3 SURGICAL ABORTION 
There are several surgical methods used in abortion care. In many countries where abortion is 
legal, vacuum aspiration is the most common method used for elective first trimester abortion 
(WHO Medical methods for termination of pregnancy 1997, WHO Safe abortion: technical 
and policy guidance for health systems 2012). However, in many countries where access is 
limited, surgical abortion is still performed using the method of dilatation and sharp 
curettage. This method is associated with substantially more serious complications such as 
surgical damage to the cervix and uterus, massive haemorrhage, incomplete abortion and 
infection compared with MVA, and the leading causes of death after abortion of infection and 
sepsis. (Shah and Åhman 2008). Using the gold standard technique of vacuum aspiration 
(manual or electric) for first trimester abortion, the success rate is 98% and equal to that of 
medical abortion, and the complication rate is only 1% (WHO safe abortion: technical and 
policy guidelines 2003, Bartlett LA et al 2004).  
Complications such as cervical tearing and uterine perforation are directly related to the force 
required to mechanically dilate the cervical canal (Tietze et al 1974, Hulka et al 1974, 
Moberg et al 1976, Schultz et al 1983). Therefore, as little force as possible should be used 
when dilating the cervix in order to cause as little damage as possible. Dilatation is often 
performed using Hegar dilators, with a rounded tip, even though these dilators do not allow a 
gradual dilatation. In a comparison between instruments, the tapered Pratt dilator was shown 
to require less force to reach equal dilatation of the cervix (Hulka el at 1974). It was also 
shown that more experienced operators used less force to dilate, corresponding to facts well 
known; skills and experience in operative technique is an important factor in minimizing 
complications. 
Before the development of medical priming agents, such as gemeprost, misoprostol and 
mifepristone, mechanical methods were used to dilate and soften the cervix before the 
surgical intervention, first described by Braxton-Hicks (Braxton-Hicks 1869). The agents 
included different roots, screws and dilators, and later intracervical tents such as the 
Laminaria, Dilaphan and Lamicel, which where osmotic dilators that were placed in the 
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cervical canal and allowed to swell and slowly dilate (Newton 1972, Lauersen et al 1982, 
Bokström and Wiqvist 1989).  
Medical priming prior to dilatation has been proven to reduce the rate of complications after 
surgical abortion, and   has been recommended for a long time prior to dilatation in women 
with an increased risk for complicated mechanical dilatation, such as young and nulliparous 
women, or women pregnant in the second trimester (Ngai et al., 1995, Fiala et al., 2007). 
Prostaglandins have also been proven to reduce the blood loss associated with vacuum 
aspiration, compared with placebo (El-Refaey H et al 1994) and Laminaria-tent (Krishna u et 
al 1986). Recently a large multi centre study proved misoprostol reduced the rate of 
complications to surgical abortion when administered as a medical priming agent prior to 
vacuum aspiration, both in nulliparous and parous women (Meirik et al 2012).   
 
1.4 MISOPROSTOL PHARMACOKINETICS 
Misoprostol is a prostaglandin E₁ analogue, initially developed to prevent gastric ulcer in 
1973. After oral administration, it is rapidly and almost completely absorbed, and converted 
to its active metabolite misoprostol acid by the liver passage. Plasma half-life after oral 
administration is 20-40 minutes (Foote et al 1995, Zieman et al 1997, Product information of 
Cytotec®). It is metabolised by the liver, and less than 1% is excreted in the urine. It has no 
known drug interactions and does not induce the P-450 cytochrome system. Toxicology 
studies show a safety margin of 500-1000-fold between lethal doses in animals and 
therapeutic doses in humans (Kotsonis et al 1985).  
Compared with most other prostaglandins, misoprostol carries fewer side-effects with no 
evidence of cardiovascular effects, and has logistical advantages, being stable at room 
temperature, widely available and cheap (Cytotec® product information). Misoprostol should 
however be manufactured and stored in a dry place, and analyses from different 
manufacturers detected samples with insufficient active ingredients (Hall 2011). Misoprostol 
can become inactive if exposed to heat or humidity for a prolonged time, and if the blister 
pack is cut and blisters inadvertently opened, the potency of misoprostol degrades within 48 
hours and continues to degrade thereafter (Berard and Fiala 2012).  
Side-effects of misoprostol are mainly gastrointestinal with diarrhoea, nausea and vomiting; 
all of which are dose-dependent, self-limiting and usually resolve 2-6 hours after intake of 
misoprostol. Fever and chills are reported after being exposed to high serum levels. There 
have been no findings of any haematological, endocrine, biochemical, immunological, 
respiratory ophthalmic or cardiovascular side-effects. Exposure to misoprostol in early 
pregnancy is associated with a variety of congenital defects. The risk of birth defects 
increases where abortion is performed with misoprostol-only regimen, as a combination of 
less efficient regimen, and exposure of higher prostaglandin doses. The teratogenicity of 
misoprostol is thought to be induced not by any toxicological effect but rather by the effect of 
uterine contractions leading to vascular disruption and the following reduction of blood 
supply to the developing embryo (Pastuszak et al 1998, Shepard 1995). The incidence of 
malformation peaks if misoprostol is used between five and eight weeks after a woman’s last 
menstrual period, and there is no association regarding anomalies with misoprostol after 13 
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weeks. The most common anomalies are clubfoot, cranial nerve injuries (Möbius syndrome) 
and absence of fingers, although the absolute risk of teratogenicity appears to be low, with 
less than 10 defects per 1000 exposures (da Silva Dal Pizzol et al 2006, Philip et al 2002, 
Gynuity 2002).  
When misoprostol is administered in low doses in term pregnancy to induce labour, there 
have been no reports of adverse effects on the foetus, apart from the speculation of a direct 
effect on the bowel and increased frequency of meconium stain in the amniotic fluid 
(Alfirevic Z and Weeks A 2014). Pharmacokinetic studies of misoprostol in breast milk show 
a peak concentration one hour after oral administration, with a milk:plasma ratio of 0.06. The 
level in breast milk then drops rapidly to become un-detectable after 4-5 hours (Vogel et al 
2004, Abdel-Aleem et al 2003). Concentrations could be lower after vaginal administration, 
and last longer after vaginal or sublingual administration; however effects on the infant are 
thought to be negligible with gastrointestinal effects being the most common.  
Due to the short half-life after oral administration, different routes of administration have 
been studied and give surprisingly different effects on plasma levels of the active substance, 
misoprostol free acid, cervical priming and uterine contractility. With vaginal misoprostol 
compared with oral, the plasma concentration does not reach the same high peak value; 
however, plasma concentrations remain elevated during a longer period of time (Aronsson et 
al 2007). The peak plasma concentration is highest after sublingual administration, whereas 
vaginal administration has a slower increase. Both sublingual and vaginal administration give 
a longer lasting elevation in plasma concentration compared with oral administration (Zieman 
et al 1997, Gemzell Danielsson et al 1999, Tang et al 2002). In correlation with lower plasma 
levels vaginal application of misoprostol results in fewer side-effects, particularly 
gastrointestinal (el-Refaey et al 1995). The effect of a single dose oral misoprostol is an 
increase in tonus, but with no development of regular contractions (Gemzell Danielsson et al 
1999, Norman et al 1991). Due to the more prolonged plasma-concentrations, the vaginal and 
sublingual route of administration are more effective in terms of stimulating regular uterine 
contractions (Zieman et al 1997, Gemzell  Danielsson et al 1999, Aronsson et al 2004), with 
vaginal administration producing the most long-lasting elevation of misoprostol acid levels 
and sublingual the most rapid uptake and highest plasma-concentration(Aronsson et al 2007). 
In all cases, in whatever doses or for which indications misoprostol is administered, NSAID 
can be used as pain relief without reducing the efficacy of the drug (Fiala et al 2005, Li et al 
2003, Creinin and Schulman 1997). 
 
1.5 INDICATIONS FOR MISOPROSTOL (OTHER THAN MEDICAL ABORTION) 
Misoprostol has been studied for a variety of indications within the gynaecological and 
obstetrical field, and is a recommended drug for treatment of incomplete miscarriage or 
missed abortion, induced abortion, cervical priming prior to mechanical dilatation, as well as 
labour induction in term pregnancies and treatment of postpartum haemorrhage (Goldberg et 
al 2001, Blanchard et al 2002). In spite of this, the holder of the patent for Cytotec®, the first 
and most widely licensed misoprostol tablet, never applied for a licence in the gynaecology or 
obstetrical field, probably due to fear of being associated with induced abortion (Weeks et al 
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2005).Today there are several new brands and companies involved in production and 
marketing of misoprostol. 
1.5.1  Cervical priming in pregnant and non-pregnant women. 
Misoprostol induces a softening “priming” effect on the cervix, making mechanical dilation 
less difficult (El-Refaey et al 1994, Ngai et al 1995). The action seems mainly to affect the 
collagen tissue of the cervix, causing disintegration and dissolution (El-Refaey 1994). As a 
priming agent, misoprostol has several advantages over other priming agents. Compared with 
osmotic dilators, misoprostol gives equal cervical dilatation in a shorter time, is easier to 
administer and is more convenient to the patient. (Krishna et al 1986, MacIsaac L et al 1999, 
Darwish AM et al 2004). Compared with mifepristone, misoprostol is actually less effective 
for cervical priming, but by far quicker acting, with a proven effect already after three hours 
vaginally (Fiala et al 2007), while mifepristone requires an interval of 24-48 hours (Rådestad 
et al 1988, Ashok PW et al 2000). Sublingual administration of 400mcg misoprostol has been 
proven equally effective compared with vaginal administration after three hours interval to 
surgery (Hamoda 2004). 
Misoprostol has also been proven effective  in non-pregnant women prior to hysteroscopy 
(Ngai SW et al 1997), but the results concerning post-menopausal women have been 
conflicting. Not all studies have separated pre- and post- menopausal non-pregnant women, 
which could be a reason for conflicting results regarding the efficacy (Thomas JA et al 2002, 
Darwish et al 2004). Study comparing defined groups of postmenopausal women prior to 
hysteroscopy, showed no efficacy of misoprostol in the postmenopausal group (Ngai SW et al 
2001, Oppegaard et at 2008), however it was shown that there is a possibility to reach 
priming effect with misoprostol after 14 days of estrogen supplement  (Oppegaard et al 
2010).  
 
1.5.2 Medical treatment of incomplete abortion and missed abortion 
Treating incomplete abortion and missed abortion with misoprostol is safe and cost-effective. 
It has been shown to shorten the time to complete expulsion compared with conservative 
expectant management, and reduces the proportion of women who need to undergo surgical 
evacuation (Blum et al 2007, Gemzell-Danielsson et al 2007). The recommended dose is 600 
mcg orally or 400 mcg sublingually as a single dose when uterine size is up to 12 weeks. For 
missed abortion, the recommended dose is 800 mcg vaginally or 600 mcg sublingually every 
three hours for a maximum of three doses (FIGO 2012). Follow up is recommended in all 
cases after  7-14 days (WHO Clinical practice handbook for Safe abortion 2014). Neither 
expectant management nor misoprostol increases risk of infection when compared with 
surgical treatment (Trinder J et al 2006).  
Complications such as infection and cervical trauma are less frequent after misoprostol 
compared with manual vacuum aspiration (Weeks et al 2005). When the miscarriage is 
diagnosed as a missed abortion, with no or little bleeding, empty gestational sac or embryo 
without cardiac activity, results of medical treatment with misoprostol have a slightly lower 
success rate of 77-89 % compared with incomplete abortion where efficacy is between 61-
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100% depending on the interval to follow-up (Gemzell-Danielsson et al 2007, WHO Clinical 
practice handbook for Safe abortion 2014). Efficacy of misoprostol treatment has been shown 
to be 96% compared with MVA 92% (Weeks et al 2005), at follow-up 7-14 days after 
treatment.  
 
1.5.3 Medical second trimester abortion and induction of labour after intrauterine 
foetal death during second and third trimester 
For second trimester induced abortion, medically induced abortion is recommended as an 
alternative to dilatation and evacuation (D&E) (WHO safe abortion technical and policy 
guidelines 2014). Medical methods in the second trimester are considered equally safe and 
efficient as surgical D&E, when D&E is performed under perfect conditions. In areas with 
limited surgically trained staff and suboptimal equipment, medical methods are to be 
preferred. Medical methods are also “minimal invasive”, whilst the surgical D&E should be 
regarded as second-line therapy. However, some abortion providers regard the medical 
methods as “traumatic”, inducing more pain during a longer period of time, as well as risking 
the woman seeing the foetus after expulsion.   
Present dose recommendations from WHO recommend dose reduction after 24 gestational 
weeks, to avoid hyperstimulation and uterine rupture, but there is limited evidence for 
recommendations beyond this week (WHO Clinical practice handbook for Safe abortion 
2014). FIGO guidelines recommend a reduction to half the ordinary dose of misoprostol in all 
women with previous uterine scarring undergoing medical second trimester abortion, when 
using misoprostol alone-regimen (FIGO 2012). Other sources recommend dose reduction 
only after 22 weeks of gestation after previous uterine scarring, but individual dose reduction 
could be indicated in women with more than one previous caesarean section (Ipas 2014 
Clinical Updates in reproductive health).  
In case of foetal death, a lower dose of 200 mcg is recommended between gestational week 
13-17, and 100 mcg between 18-26 weeks. After 26 gestational weeks, the same doses are 
recommended as for labour induction (FIGO 2012). Some recommendations state however 
that higher doses can be used after IUFD since there is a possible decrease in uterine 
sensitivity , and doses of 200 mcg  (up to 34 gestational weeks) or 100 mcg vaginally (from 
34 gestational weeks) have been used with good result. There is evidence of induction of 
labour after late IUFD using a combination of mifepristone and misoprostol, with good 
results and short time to delivery after start of misoprostol treatment (Wagaarachchi et al 
2002).  
 
1.5.4 Labour induction 
Prostaglandins have been proven useful for induction of labour when the cervix is 
unfavourable, but the prostaglandins registered and labelled for this purpose have all been 
expensive and unstable at room temperature (Keirse 1993, MacKenzie 1997). In comparison, 
misoprostol has been proven to have higher efficacy compared with both oxytocin and other 
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prostaglandins for inductions of labour at term (Alfirevic Z and Weeks A 2014), when 
outcome has been vaginal birth within 24 hours. Misoprostol has also been shown to be 
associated with a lower risk of caesarean section compared with other prostaglandins. There 
is however a fear for increased risk of uterine rupture, and misoprostol has therefore not been 
recommended to women with previous caesarean section (Alfirevic Z and Weeks A 2014). 
 To avoid hyper stimulation, recent research has focused on very low vaginal doses of 25 
mcg, and oral 25-50 mcg misoprostol. When comparing the different routes of 
administration, oral misoprostol had a lower risk of low apgar score <7 at five minutes. 
Solution of 200 mcg tablets of Cytotec® (Pfizer, NY, USA) has been shown to be suitable for 
oral administration of misoprostol, and gives a high accuracy of the doses (www.mpa.se, 
www.sfog.se).  Due to the regimen with administration of misoprostol every second hour and 
recommendation of hospitalisation and foetal heart-monitoring, there might be a practical 
aspect when choosing misoprostol for induction of labour – particularly if induction cannot 
be initiated in the morning.  
 
1.5.5 Prevention and treatment of postpartum haemorrhage 
Having a similar effect on the myometrium and uterine contractility as oxytocin, misoprostol 
is an alternative for prevention and treatment of atonic uterus. Misoprostol has logistical 
advantages compared with oxytocin, as it is stable in room temperature, (at least if the 
product is not exposed to a humid environment), and can be administrated orally or 
sublingually, thus not requiring intravenous access or skilled personnel. Misoprostol has been 
proven efficient for prevention of postpartum haemorrhage, but is less effective than oxytocin 
(Gulmezoglu et al 2001, Alfirevic et al 2007, Tuncalp et al 2012). In treatment of postpartum 
haemorrhage, misoprostol does not have an advantage regarding efficacy over oxytocin 
(Widmer et al 2010, Blum et al 2010, Winikoff et al 2010). Misoprostol is a safer alternative 
compared with ergometrine and prostaglandin F2 alpha, due to the cardiovascular and 
pulmonary side-effects of these drugs (Goldberg et al 2001). In contrast to oxytocin, 
misoprostol does not have a decreasing effect on blood pressure. The common side effects of 
misoprostol; fever, chills, nausea and diarrhoea are uncomfortable but self-limiting and 
harmless in the longer perspective (Durocher et al 2010). Misoprostol has also been tried 
intraumbilically, for conservative treatment of retained placenta (Rogers et al 2007). 
Recently, misoprostol was approved by the EMA for treatment of post partum haemorrhage 
(Hemoprostol®, LinePharma, Paris, France). 
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1.6 MIFEPRISTONE PHARMACOKINETICS 
Mifepristone is a synthetic anti- progesteron which works as an antagonist to progesterone 
and glucocorticoid at receptor level (Baulieu and Ullman 1985). Following oral 
administration, absorption is rapid with peak concentration after one to three hours, and half-
life of 20-40 hours (Lähteenmäki et al 1987, Heikinheimo et al 1990, van Look and 
Bygdeman 1989). Absorption after vaginal administration is insufficient for reaching clinical 
effect (Heikinheimo et al 1987). Mifepristone metabolites are excreted in the urine (10%) and 
in the faeces via the biliary system (90%). Its affinity to the progesterone receptor is five 
times that of natural progesterone, and to the glucocorticoid receptor with an affinity of three 
times that of dexamethasone.  It also binds to a lesser extent to the androgen receptor 
(Moguilewsky and Philibert 1985, Lähteenmäki et al 1987). Mifepristone antagonizes the 
effect of progesteron and glucocorticoid by occupying the receptor, but without stimulating 
the gene transcripton (Spitz and Bardin 1993, Christin-Maitre et al 2000).  Mifepristone 
behaves as a pure antagonist with minimal agonist activity (Moguilewsky and Philibert 
1985).  
Anti- glucocortiocid activity has been proven following a single dose of 400 mg of 
mifepristone, which lasts for at least 24 hours, affecting both the central actions of cortisol 
(inhibition of feedback control) and peripheral effects; however no effect is seen on the 
mineral-corticoid axis (Gaillard et al 1984, Raux-Demay et al 1990). The inhibitory effect on 
the negative feedback system counteracts the effects in healthy individuals, increasing ACTH 
(adrenocorticotropic hormone) secretion and re-establishing an equilibrium (Healy et al 
1985). When treating patients with adrenal failure and long-time corticosteroid replacement 
therapy, this anti-glucocorticoid effect can be counteracted by administration of >1 mg 
dexamethasone (Raux-Demay 1990), or by increasing the dose of the steroid medication 
(Davey 2006). The only contraindication to treatment with mifepristone is severe, poorly 
controlled asthma; due to fear of exacerbation of the life-threatening condition (Christin-
Maitre et al 2000, Sitruk-Ware 2006). Asthma treated with inhaled corticosteroid is not a 
contraindication (Creinin and Gemzell Danielsson 2009). There have been cautions when 
treating nursing mothers, due to the anti-glucocorticoid effect.  Mifepristone crosses the 
placental barrier, resulting in maternal:fetal ratios in plasma of 9:1 to 17:1. Foetal aldosterone 
levels are elevated for 24 hours after single dose of 600 mg mifepristone, but no effects have 
been shown on foetal progesterone, estradiol or cortisone levels (Hill et al 1991).  
Mifepristone does not seem to have teratogenic effects, in case of exposure of an ongoing 
pregnancy (Bernard et al 2013). 
Mifepristone was shown to effectively interfere with the viability of early pregnancy 
(Herrman 1982, Kovacs et al 1984). Treatment with mifepristone will serve as an antagonist 
to the progesterone produced by the corpus luteum in early pregnancy and in the placenta, by 
reversing the hyperpolarisation of the cell membranes in the myometrium and stimulating the 
gap junction formation (Garfield and Baulieu 1987, Garfield et al 1988, Norman et al 1991), 
thus increasing the sensitivity of the myometrium to prostaglandin (Bygdeman and Swhn 
1985, Swahn and Bygdeman 1988). Mifepristooe also induces an endogenous production of 
prostaglandines in the deciduas (Norman et al 1991). In addition, mifepristone has a slow 
priming effect on the cervix (Bygdeman et al 1991). Studies have proven that a mifepristone 
100 mg single dose as almost equally effective, or five doses of 25 mg administered with 12 
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hours intervals as equally effective as doses of 200 mg or higher for termination of 
pregnancy, although reducing the dose further resulted in decreased efficacy (WHO task 
force on post -ovulatory methods of Fertility Regulation 1993, WHO task force on post-
ovulatory methods of Fertility Regulation1991, von Hertzen et al 2009). 
 
1.7 INTRAUTERINE CONTRACEPTION 
Intrauterine contraception is the most widely used reversible contraceptive method in the 
world (NICE clinical guidelines 2005). The effectiveness of long-acting reversible 
contraception (LARC) is superior to short-acting contraception and is not altered in young or 
nulliparous women (Winner et al 2012). IUC is also safe and highly acceptable  in younger 
women, with rapid return of fertility when discontinuing, and no increased risk of tubal 
infertility (Rybo et al 1993, Mansour et al 2011, Secura et al 2014). A smaller uterus does not 
reduce the efficacy of an IUC, and both efficacy and continuation rates of IUC are similar for 
nulliparous and parous women (Duenas et al 1996, Meirik et al 2001). The only 
contraindication to intrauterine contraception, apart from established pregnancy is PID 
(pelvic inflammatory disease), septic abortion and puerperal sepsis until the infection is fully 
resolved (WHO technical and policy guidelines for health systems 2012). There is no 
increased risk of PID in IUC users, after the first 20 days following insertion (Farley et al 
1992, Grimes et al 2000). The incidence of PID in LNG-IUS (Levonorgestrel releasing 
intrauterine system) users is significantly lower than in women using a Cu-IUD (copper-
coated intrauterine device), possibly due to the cervical mucus, rendering it less permeable to 
sperms and pathogens (Andersson et al 1994)  
The most common IUCs used today are the copper coated intrauterine devices (Cu-IUD) in 
different models (life-span 5-10 years), and the Levonorgestrel-releasing system (LNG-IUS), 
Mirena (lifespan 5 years).  There are also frameless copper-devises, which are “anchored” in 
the fundal region. A copper-coated intrauterine ball (IUB), which has a small diameter when 
inserted and that curls to a spherical shape when released in the uterine cavity has recently 
been developed (Baram et al 2014). In some parts of the world, copper devises without treads 
are still common (Grafenberg ring) (Searle 2014). A new LNG-IUS has been developed in 
recent years, (Jaydess®), releasing a lower levonorgestrel dose, and with a life-span of three 
years. Among the IUCs it is only the Cu-IUDs which have been shown to be effective for 
emergency contraception. Cu-IUD should be remembered and offered, being the most 
efficient emergency contraception available (Raymond Li et al 2014). 
The hormonal device was developed to reduce expulsion and reduce the side effects of 
ordinary copper-IUDs. The first hormonal IUS was Progestasert®, which had a lower 
pregnancy rate compared with inert IUC, as well as reduced menstrual bleeding, however, the 
life-span was only 12 months (Place et al 1974).  Levonorgestrel has a more profound and 
uniform effect on the endometrium, and is not metabolized as rapidly as progesterone. An 
IUS, releasing levonorgestrel 20 mcg/24 hours was developed, with similar high 
contraceptive efficacy, positive effects on reducing menstrual bleeding and dysmenorrhoea 
but with a life span of 5 years (Nilsson CG 1975). The LNG-IUS has been shown to reduce 
heavy menstrual bleeding in women with and without uterine leiomyomas, to also reduce 
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menstrual pain  in women with adenomyosis and endometriosis, and is superior to systemic 
progestins to treat endometrial hyperplasia, as well as to reduce the risk of endometrial cancer 
and cervical cancer (Hubacher and Grimes 2002, Heikinheimo et al 2012, Castellsague et al 
2011). In a large American study including almost 10000 women, the 20mcg LNG-IUS 
proved to be the most effective and acceptable contraceptive choice with the highest 
continuation rate (Winner et al 2012). One of the areas for improvement in medical abortion 
is post abortion bleeding, which is unpredictable, and may be heavy and long-lasting. 
Therefore, the effect of post abortion contraception and in particular IUCs is important to 
study. 
 
1.8 POSTABORTION CONTRACEPTION 
Contraception use should be initiated immediately post-abortion to reduce the risk of repeat 
unwanted pregnancy and abortions. Ovulation can occur as early as 8 days after induced 
abortion, and 83 % ovulate during the first cycle (Schreiber et al 2011, Lähteenmäki et al 
1978). A majority of women reinitiate sexual activity within two weeks after an abortion 
(Boesen et al 2004). The most effective contraception methods in terms of reducing the risk 
of repeat abortion are long-acting reversible contraception (LARC), i.e. copper intrauterine 
device (Cu-IUD), levonorgestrel-releasing intra-uterine system (LNG-IUS), implants and 
injectables (Langston et al 2014, Secura et al 2014).  
Young and nulliparous women are less likely to use an IUC after abortion, although it has 
been proven as safe and effective for this group of women (Secura et al 2014). Those women 
who have had an IUC inserted post abortion, are much less likely to have a repeat abortion 
(Roberts et al 2010, Cameron et al 2012).  Those methods also have a higher continuation 
rate compared with other short-acting methods such as contraceptive pills (Cameron et al 
2012). Hormonal method can be started on the same day as the abortion with no risk of 
affecting the abortion treatment (Gaffield et al 2009, WHO Medical eligibility criteria for 
contraceptive use 2010, Tang et al 2002). Intra-uterine contraception (IUC) can be inserted 
immediately after an uncomplicated surgical abortion, although there is a slightly elevated 
risk of expulsion with increasing gestational duration (Bednarek et al 2011, Grimes et al 
2010). After medical abortion, the standard clinical routine has been to insert IUC at the 
follow-up visit three to four weeks after the abortion.  This is complicated by the increased 
number of women not returning for the follow-up and IUC insertion, and several studies 
indicate that the proportion using IUS is higher after immediate insertion (Stanek et al 2009, 
Bednarek et al 2011, Cameron 2012).Thus, the possibility of earlier insertion of IUC after 
medical abortion is crucial to help women avoid a repeat unwanted pregnancy. 
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2 AIMS OF THE STUDY 
 
The overall aim of the thesis is to increase access to intrauterine contraception and safe 
abortion methods. Misoprostol has become the drug of choice for various indications in the 
gynecological and obstetrical field; however, the optimal dosages for several of the 
indications remain undefined. In the combined regimen of mifepristone and misoprostol for 
medical abortion misoprostol is also considered safe  for nursing mothers and their infants, 
while  knowledge on the transmission of mifepristone has been limited. For women 
undergoing medical abortion, one of the most important aspects is future contraception, of 
which IUC is one of the most efficient and acceptable options. Investigating the safety and 
limitations of immediate/early IUC insertion is crucial to ensure women the possibility of 
choosing a medical method for termination of pregnancy as well as IUC for post-abortion 
contraception.   
 
The specific aims of this thesis were therefore  
 To investigate the efficacy of priming with misoprostol in nulliparous, non-pregnant 
women prior to insertion of a Cu-IUD 
 To investigate the transmission of mifepristone to human breast-milk in women 
undergoing medical abortion 
 To study the timing of insertion of IUC after first trimester medical abortion, and 
 To define the optimal interval and route of administration of misoprostol for cervical 
priming prior to mechanical dilatation and vacuum aspiration. 
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3 MATERIAL AND METHODS 
 
The studies were conducted at the department of Obstetrics and Gynaecology, Sesam 
(outpatient unit for sexual and reproductive health) and C21 day care clinic, Karolinska 
University Hospital, the WHO collaboration centre, Department of Women’s and Children’s 
Health, Karolinska Institutet, and (study III) GynMed Ambulatorium Clinic in Vienna and 
Salzburg, Austria. Analyses of mifepristone in breast milk were performed at the 
Biomedicum Institute in Helsinki, Finland (Study III). The studies were approved by the 
regional ethics committee at Karolinska Institutet and by the Swedish Medical Product 
Agency (Läkemedelsverket). All women gave their written informed consent before being 
enrolled into the studies.  
Study design 
Study I, III and IV were randomized controlled trials. Study III was a phase II 
pharmacokinetic study. 
 
Table I. Overview of the studies 
Study and topic Inclusion 
date 
% Nulliparous No of 
patients  
Gestational 
length 
Misoprostol dose Mifepristone 
dose 
I  
IUD insertion 
after misoprostol 
Sept 2004 – 
July 2006 
100% 80 Non-pregnant 400 µg 
sublingually 
- 
II 
Mifepristone in 
breast milk 
 
June 2003 – 
August 2006 
 
0% 12 47 – 123 days 400 µg orally or 
800 µg vaginally 
600 mg or  
200 mg 
III  
IUC after 
medical abortion 
Feb 2007 – 
Oct 2010 
34 % 129 27-63 days 
 
800 µg vaginally 200 mg 
IV 
Misoprostol prior 
to surgical 
abortion 
June 2007 – 
mars 2014 
100 % 184 42 – 85 days 400 µg 
sublingually or 
vaginally 
- 
 
 
3.1.1 Study I 
This study was a randomised, controlled trial, comparing treatment with sublingual 
misoprostol and diclofenac to diclofenac-alone given one hour prior to insertion of a copper –
intra-uterine device (Cu-IUD).  
A total of 80 women were recruited between September 2004 and July 2006 among healthy 
nulliparous women over 18 years of age, requesting a cu-IUD (Nova-T, Schering AG, 
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Berlin). Exclusion criteria were any signs of genital infection, contraindication to 
misoprostol, or a positive pregnancy test. Patients were randomised to either treatment with 
400 mcg sublingual misoprostol and 50 mg diclofenac (PO), or to 50 mg diclofenac (PO). 
The medication was administered by a study nurse one hour before the IUD insertion. The 
drug administered was unknown (blinded) to the investigators, but not to the women. The 
information was kept concealed from the investigating doctors until the study was completed.   
The main outcome was measured as the cervical resistance and the ease or difficulty of IUD 
placement experienced by the investigator and was classified as “easy”, “moderate” or 
“difficult”.  
Cervical dilatation was recorded prior to the insertion of the IUD. The degree of dilatation 
was determined by whether or not Hegar dilators with a diameter of 4 mm (corresponding to 
the diameter of the uterine sound) or smaller could pass through the internal cervical os 
without resistance. Any resistance or need for dilatation was recorded. Pain was indicated by 
the women on a visual analogue scale (VAS) graded from 0 to 10, 0 representing no pain at 
all and 10 worst possible pain imaginable. Side effects such as nausea, diarrhoea, skin rash, 
fever/shivering, bradycardia or syncope were recorded by the study nurse after questioning 
the patients.  
Women were asked to keep daily records of pain, bleeding and any side effects experienced 
after the IUD insertion until the follow-up visit four weeks after the insertion. At the follow 
up visit a vaginal examination was performed to check that the IUD was in place, and the 
diary was collected.  
The main outcome of the study was the cervical resistance during cu-IUD insertion as judged 
by the investigator, who was blinded to treatment allocation. Secondary outcomes included 
the effect of treatment on cervical dilatation, side effects, pain, bleeding and acceptability.  
 
3.1.2 Study II 
This study was a pharmacokinetic study aimed at investigating the levels of mifepristone in 
breast milk from women undergoing medical abortion.  Between June 2003 and August 2006, 
12 healthy lactating women over 18 years of age requesting medical termination of 
pregnancy were recruited (six in Stockholm and six in Vienna) The laboratory analysis of 
mifepristone levels in plasma and breast milk were performed during September 2008 at the 
Biomedicum institute, Helsinki, Finland.  
Medical termination of pregnancy was performed according to clinical routine, however, 
during the recruitment period, the protocol concerning mifepristone dose changed in 
Stockholm from 600 mg to 200 mg. On day one of treatment the women received either 600 
mg (n=10) or 200 mg (n=2) mifepristone orally, followed by 400 mcg misoprostol orally or 
800 mcg misoprostol vaginally 36-48 hours later (treatment day 3) depending on the length of 
gestation. At this time, the clinical routine was to advise the women to discard breast milk for 
three days following mifepristone administration. The women in the study were asked to 
collect 10-20 ml of milk from each pumping session during the first three days following 
mifepristone treatment and if possible continue to sample breast milk for another four days up 
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to seven days following treatment. The samples were frozen and stored at -20⁰  C until 
analysed. Serum samples were collected from four of the women on day three.  
In the analysis, mifepristone was separated from its cross-reacting metabolites using 
Chromosorb® column chromatography, after which the levels of mifepristone in serum and 
breast milk were quantified by radioimmunoassay (RIA). The breast-milk samples were 
diluted with phosphate-buffered saline in the ratios 1:10, 1:20 and 1:50 to reduce the 
influence of fat. The detection limit of the mifepristone assay when using milk was 0.013 
µmol/l. The intra- and inter-assay co-efficient of variation in these assays were 11.8 and 
19.6%, respectively.  
The main outcome was the levels of mifepristone in breast milk quantified in 
radioimmunoassay. 
 
3.1.3 Study III 
This was a randomised, controlled trial investigating the safety and efficacy of early IUC 
insertion on day 5-9, compared with routine delayed IUC insertion 4 weeks after medical 
abortion. A total of 129 healthy  women over 18 years of age, requesting medical termination 
of pregnancy up to gestational length of 9 weeks (63 days) and an IUC as post-abortion 
contraception were recruited between February 2007 and October 2010. Women with a poor 
understanding of the Swedish language or abnormal pregnancies were excluded from 
participating, as well as women planning  a pregnancy within the next year. Women were 
free to choose between the Cu-IUD (NovaT, Bayer, Berlin, Germany) or the LNG-IUS 
(Mirena®, Bayer AG, Berlin, Germany), and within each stratum randomised to either early 
insertion or delayed insertion in a ratio of 1:1. The randomisation list was kept concealed 
from the study investigators until the study was completed.  
The medical termination of pregnancy was performed according to clinical routine. All 
women were screened for bacterial vaginosis and Chlamydia infection, and treated if positive 
but not excluded from participation. Gestational age was determined by transvaginal 
ultrasound. Women were administered 200 mg mifepristone orally at the clinic, and the day 
of mifepristone treatment was counted as day one. 36 to 48 hours later women self-
administered 800 µg vaginally either at home or at the clinic. Before administration of 
misoprostol, analgesics according to clinical routine were also administered. All women were 
advised to abstain from intercourse until insertion of the IUC. An ultrasound examination was 
performed prior to insertion of the IUC, and the thickness of the endometrium and signs of 
remnants of gestational products were recorded. Women with continuing pregnancy or 
missed abortion with intact gestational sac on the day of planned insertion, with surgical 
intervention or genital infection after the abortion treatment were excluded from the trial. 
Intensity of pain was recorded as judged by the patient on the visual analogue scale (VAS) 
from zero to ten directly after the insertion. Serum haemoglobin (S-Hb) and human chorion 
gonadotropin (S-hcg) were determined on day one, on the day of IUC insertion and at the 
four week follow-up visit after insertion. Women were asked to keep a daily diary of the 
bleeding pattern as well as any other adverse event or concomitant medication. 
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The patients were scheduled for a follow-up visit four weeks after the IUC insertion. The 
diary was collected from the patients. Any complications such as expulsion, uterine 
perforation, and genital infection were recorded. The patients were contacted by telephone 
after six months, and answered a questionnaire about pregnancy, expulsion, bleeding patterns, 
pelvic pain, pelvic infections, continued use and overall satisfaction concerning the 
contraceptive method.  
The main outcome in the study was the incidence of expulsion, and secondary outcomes were 
rates of insertion and complications after insertion, as well as differences in bleeding patterns 
and compliance during the first six months of use.  
 
3.1.4 Study IV 
This study was a randomised placebo-controlled trial aiming at investigating the optimal 
priming interval and administration route of misoprostol prior to surgical abortion. 184 
patients were recruited between June 2007 and march 2014 among nulliparous women 
requesting surgical termination of first trimester pregnancy (gestational week 6 - 13). In those 
who had been pregnant preciously, all pregnancies had ended during the first trimester, either 
by termination of pregnancy or miscarriage. Women with general good health, over 18 years 
of age and with a normal first trimester pregnancy who opted for surgical termination of 
pregnancy were offered to participate in the study. Exclusion criteria were any 
contraindication for misoprostol, previous history of surgery to the cervix and uterus (other 
than vacuum aspiration), untreated genital infection or an abnormal pregnancy. Women 
participating in the study were randomised into four different treatment groups, receiving 
misoprostol either sublingually or vaginally, and priming time either one or three hours. The 
randomisation list was kept concealed from the investigating doctors until the study was 
completed.  
The patients received 2 tablets of misoprostol, either vaginally or sublingually, and two 
identical placebo-tablets, thus the route of administration of active substance was concealed. 
The patients were allowed to administer the tablets themselves. According to clinical routine, 
the patients also received 100 mg of diclofenac orally for pain relief. Immediately before 
surgery, the women were asked if they had experienced any side effects, and which route of 
administration they would have preferred.  
The exact priming time and signs of preoperative bleeding were recorded. Cervical dilatation 
and vacuum aspiration was performed by one of two investigating physicians. The vacuum 
aspiration was performed under general anaesthesia according to clinical routine. Dilatation 
was performed using Pratt-dilatators and the resistance of the cervix was objectively assessed 
using a force-sensing handle attached to the dilator (tonometer). The cervical canal was 
dilated with dilators from 6.3 mm (19 French) up to 9.7 mm (29 French), or in some cases 
with pregnancies over 11 weeks of gestation up to 11 mm (33 French). The peak force of 
each dilator was recorded. The cumulative force was calculated by adding the peak force for 
each dilator up to 9.7 mm. Baseline dilatation was considered to be the largest dilator that 
could enter the cervical os using a force less than 8N. If the smallest dilator could not enter 
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the cervical canal, the baseline was considered to be 4.1 mm, which is the mean baseline in 
untreated, nulliparous women.  
The main outcome in the study was the baseline dilatation of the cervix after medical 
priming. Secondary outcomes were cumulative force and peak force needed for mechanical 
dilatation of the cervix, intraoperative blood loss, duration of surgery and dilatation, bleeding 
prior to surgery, side-effects from medication and preference concerning the route of 
administration.  
 
3.2 STATISTICS 
Study I: To evaluate the differences between the two groups with regard to cervical resistance 
indicated by difficulty or ease of insertion, judged by the investigators, the Fisher’s Exact test 
was used (one-sided mid-P-value). The Fisher’s Exact test (two-sided) or the Chi-squared test 
was used for independent nominal data such as side effects and overall experience from the 
insertion as judged by the patient. Continuous variables were compared using the unpaired t-
test, and discrete numerical values were compared using the Mann-Whitney U-test.  
Study III: To evaluate the differences between the early insertion group and the delayed 
insertion group, regarding independent nominal data such as expulsion, side-effects and 
compliance, the Chi squared test was used. Continuous variables with normal distribution 
such as age, and discrete numerical variables such as parity and bleeding patterns were 
compared using the Mann-Whitney U-test.  
Study IV: To evaluate differences between the groups, all groups were compared to the 
others using the Student’s t-test (two-sided). Continuous variables such as age and discrete 
variables such as bleeding before surgery were compared using the Mann-Whitney U test. 
For testing if the group of sublingual treatment 1 hour was non-inferior to 3 hours, a non-
inferiority test was performed. The non-inferiority test was assessed through a two-sided 95% 
confidence interval. A difference of less than 0.5 mm in baseline dilatation was considered 
clinically irrelevant. The non-inferiority test was also performed for peak force, where a 
difference of less than 5N was considered clinically irrelevant, and a cumulative force of less 
than 10 N was considered clinically irrelevant. 
Differences were considered statistically significant if p-value was <0.05.  
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4 RESULTS 
 
4.1.1 Misoprostol for cervical priming (study I and IV) 
Following priming with misoprostol administered sublingually one hour before the procedure 
to nulliparous women prior to insertion of an IUD, IUD insertion was significantly more 
often judged as easy by the physician (p=0.039). The insertion was judged to be easy in 29/40 
women in the misoprostol group compared with 22/40 women in the control group, and 
intermediate or difficult in 10/40 women in the misoprostol group compared with 18/40 in the 
control group.  The assumption of the blinded investigators was that 27 of the women in the 
misoprostol group and 20 of the women in the control group had received treatment, 
indicating that insertion of an IUD does not need to be difficult, even in nulliparous women. 
However, there were two failed insertions in the control group, and none in the misoprostol 
group (ns). 
There was no difference in pain estimated by the patients; median VAS estimation was 7 in 
the misoprostol group and 6.5 in the control group (ns). Shivering and diarrhoea were more 
common in women treated with misoprostol (p= 0.0084, and p= 0.075, respectively). There 
was no difference in bleeding or pain during the first month after the insertion. There were no 
pelvic infections or expulsions in the trial.  
In study IV it was further evaluated if priming with sublingual misoprostol prior to surgical 
abortion could reach significant efficacy already after one hour. Sublingual priming with 
misoprostol was shown to be as effective after one hour as after three hours, with  no 
difference in baseline dilatation (p=0.45), peak force (p=0.73), or cumulative force (p=0.68). 
Sublingual one hour priming was also proven to be non-inferior compared with sublingual 
three hours priming for baseline dilatation (CI -0.42 – 0.95), peak force (CI -4.1 – 2.9) and 
cumulative force (CI -14.4 – 9.5).  Also, sublingual priming was more effective than vaginal 
when priming time was reduced to one hour with greater baseline dilatation (p=0.038) and 
less cumulative force was needed for dilatation p=0.048). 
 
Table 4. Effect of misoprostol on cervical dilatation regarding route of administration and priming 
interval (Study IV).   
Study group SL 1 hour 
(n=45) 
SL 3 hours 
(n=46) 
PV 1 hour 
(n=43) 
PV 3 hours 
(n=44) 
Significance 
Baseline 
dilatation (mm)  
7.9 (1.4)
 1
 7.6 (1.8)
 
 7.2 (1.5)
 1
 7.9 (1.5) 
1
p=0.038  
(CI 0.037-1.25) 
 
Peak force (N) 16.5 (8.0) 17.1 (8.4) 20.3 (10.6)
 1
 15.5 (8.2)
 1
 
1
p= 0.021 
(CI 0.73-8.94) 
Cumulative 
force (N) 
51.9 (27.0)
 1
 54.4 (29.2) 64.6 (31.3) 
1,2
 47.1 (23.3)
 2
 
1
p=0.048 
(CI 0.13 - 25.3) 
2
p=0.005 
(CI 5.45-29.6) 
SL=sublingual, PV per vagina 
Results are expressed as mean (SD). Figures indicate significant differences between groups 
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There was a clear correlation between the results of baseline cervical dilatation and 
cumulative force (Study IV).  
Baseline dilatation 
(mm) 
Cumulative force (N) 
 
The proportion of women who had started bleeding before surgery was significantly reduced 
when priming time was shortened to one hour when comparing the sublingual groups 
(p=0.0008). Significantly fewer women reported abdominal pain in the vaginal administration 
group after a priming time of 1 hour (p=0.0001). The groups did not differ concerning the 
duration of surgery, amount of bleeding and the rate of side-effects, such as nausea and 
shivering. Women in our study preferred vaginal treatment, as they disliked the taste of the 
misoprostol tablets. (p=0.0001). 
 
Table 3 side-effects (Study IV).  
Study group SL 1 hour  
(n=45) 
SL 3 hours  
(n=46) 
PV 1 hour  
(n=43) 
PV 3 hours  
(n=44) 
Significance 
Bleeding/expulsion 
before surgery 
2 (4.4%)
1
 15 (33%)
1
 3 (7.0%) 8 (18%) 
1
 P=0.0008 
Abdominal pain 30 (67%)
1
 31 (67%)
2
 6 (14%)
1,2,3
 24 (57%)
3
 
1
 P<0.0001 
2
 P<0.0001
 
3
 P<0.0001 
Freezing/shivering 6 (13%) 2 (4%) 2 (5%) 3 (7%) ns 
Nausea/vomiting 11 (24%) 9 (20%) 8 (19%) 4 (9%) ns 
SL= sublingual,  PV= per vagina 
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4.1.2 Levels of mifepristone in human breast milk from women undergoing 
medical abortion (study II) 
Declining concentrations were detected for up to 7 days following the higher (600 mg) dose 
of mifepristone. Six of the 12 women managed to collect the first samples during the first 6 
hours after intake, and these samples were found to have the highest concentrations of 
mifepristone, ranging from 0.063 to 0.913 µmol/l. 
 
 
Levels of mifepristone in samples of breast milk collected from a lactating woman undergoing medical abortion on days 1–7 
following intake of 600 mg of mifepristone (StudyII) 
 
Two women receiving the lower dose (200 mg) of mifepristone had mifepristone 
concentrations in breast milk under the detection limit, already during the first day following 
intake. Only very low levels were also detected  following intake of the higher dose after day 
3. The milk:serum ratio of mifepristone ranged from <0.013:1 to 0.042:1 on day three. 
Calculating with the highest detected concentration, in a whole day’s milk-consumption for a 
baby of 6-12 months, the RID (relative infant dose) would only be 0.5-1.5%.  
 
4.1.3 IUD and post-abortion contraception (study I and III) 
There was a high acceptability among the young nulliparous women undergoing insertion of 
a cu- IUD in study I. No severe complications such as pelvic infections, perforation or 
expulsion were diagnosed among the study patients, and of the 77 successful insertions, only 
one patient was lost to follow up. A large majority, 82 % answered that they would go 
through an insertion of an IUD again, whereas 6.5% stated they would not.  
For women undergoing medical abortion up to 9 weeks gestation, it was proven to be equally 
safe to have the IUD inserted during the first week after the abortion (study III). There was no 
difference in expulsion rate between early insertion on day 5-9 (9.7%) compared with routine, 
delayed insertion after 3-4 weeks (7.4%). These figures include both complete and 
incomplete expulsions.  
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Table 2. Outcomes of Early versus Delayed IUC insertion after medical abortion (Study III). 
 
 
 
Early insertion was also proven safe, with no increased risks of pelvic infections, perforations 
or heavy and prolonged bleeding after the medical abortion. No risk association could be 
identified among the women with expulsion, with regard to parity or ultrasound findings such 
as endometrial thickness. When comparing the copper-IUD with LNG-IUS, there were fewer 
days with heavy bleeding post abortion in the LNG-IUS group (p<0.01) already during the 
first 4 weeks after the abortion compared with the copper-IUD group. 
 More women did not show up for IUC insertion in the delayed group (n=7, 11%) than in the 
early group (n= 1, 1.5%) (p=0.03) (Proportion difference 10%, 95% CI: 1.8-20.6%, p=0.015). 
Also, the women in the delayed insertion group were more likely to have had an unprotected 
intercourse prior to the IUC insertion (p=0.015). Of the women in the delayed group, 41% 
had unprotected intercourse after the abortion and prior to the IUC insertion, compared with 
16% in the early group.  
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5 DISCUSSION 
 
5.1 GENERAL ASPECTS 
Improving women’s knowledge and access regarding LARC is crucial to improving women’s 
health and to avoiding unnecessary unplanned pregnancies. After abortion fast initiation of 
LARC will prevent repeat abortion. IUC is underused, and particularly among younger 
women – a group that generally has more failures of other contraceptive methods, and who 
are overrepresented in the group of women suffering from serious adverse maternal outcomes 
after abortion, including maternal deaths. After medical abortion, there has been little 
evidence on the best timing for IUC insertion and proof of safety if initiated shortly after the 
abortion. This is again of particular interest, where surgical procedures should be avoided due 
to sub-standard care and where women may have difficulties in travelling long distances for 
abortion.  
Misoprostol has been proven to be a useful prostaglandin analogue in many areas of the 
gynaecological and obstetrical field. Compared with the initial prostaglandins, the modern 
substances have a longer duration of action and do not have the same side-effects regarding 
the cardiovascular system. When the primary substances need to be administered 
intravenously or intraamniotically, the modern prostaglandin E₁ analogue (misoprostol) can 
be administered orally, sublingually and vaginally.  In comparison with other modern 
prostaglandin analogues, misoprostol has logistical advantages of being available in tablets, 
possible to use orally, stable at room temperature, widely available around the globe and 
cheap. Studies in regard to efficacy, plasma concentrations and half –life in pregnancy have 
been performed previously in recent years; however there has been a lack of studies on 
clinical efficacy after certain routes of administration, as well as of a defined optimal dose 
and priming interval for surgical abortion as well as use in non-pregnant women.  
Understanding of the pharmacokinetics of misoprostol, as well as defining the optimal doses 
and routes of administration, is crucial to define efficacy and for acceptance of its use, and to 
ensure safety of the drug. Spreading the information of proper use of misoprostol, and to 
some extent mifepristone in combined regimens, will provide women with safe and effective, 
minimal invasive treatment in a variety of gynaecological and obstetrical indications, and 
very importantly – give women with no access to safe, legal family planning services a safe 
option for self-administration in case of  need for an abortion. There is a need for simplified 
regimens and guidelines that can be made available to the population, including self-
diagnosis of pregnancy, home-use of correct doses of misoprostol (and mifepristone where 
available), self-assessment of complete abortion and prompt access to post abortion 
contraception.  
 
5.2 MISOPROSTOL FOR CERVICAL PRIMING 
Priming of the cervix prior to surgical procedures may be indicated depending on the 
intended procedure or on the history of the woman. It was recently shown that priming with 
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misoprostol reduces the complications rate for all women, nulliparous and multiparous, when 
undergoing first trimester surgical abortion (Meirik et al 2012). Prior to hysteroscopy, 
priming is usually desired, and misoprostol has also been proven effective  in non-pregnant 
women (Ngai et al 1997, Fiala et al 2007). Prior to insertion of IUC, priming is not always 
necessary, but can be desired in a subgroup of nulliparous women, i.e. women with cervical 
stenosis, amenorrhea or after a failed attempt. 
In study I, we concluded that the insertion of IUC is usually also uncomplicated in 
nulliparous women; however, there was a priming effect on the cervix, measurable as 
technically easier insertion already after one hour priming with sublingual misoprostol. There 
was no effect on the patient’s estimation of pain during the insertion, but if insertion is 
facilitated, a technically more complicated insertion that often takes longer time can be 
avoided. Short duration of pain was an important factor for the 79% of patients that stated 
that they would go through the procedure again if necessary. Since misoprostol has known 
side-effects (particularly after rapid increase in plasma levels, such as after sublingual 
administration) such as nausea, diarrhoea, abdominal pain and chills, it can be argued that 
routine administration is not indicated before IUC insertion. When insertion fails, however, 
this rapid efficacy can be used for treatment and a new attempt of insertion can already be 
made during the visit. If a difficult insertion is anticipated, and medical priming with 
misoprostol is planned, misoprostol can be administered vaginally, but the priming interval 
should then be increased to three hours based on data from pregnant women (study IV). In 
our study we used only the smaller copper-IUD Nova-T, to ensure comparability. When 
inserting the larger LNG-IUS (Mirena), the risk of failed insertion and the need for medical 
priming could increase. The importance of facilitating IUC insertion is demonstrated by the 
huge interest in our study (study I, Sääv et al 2007) which has been followed by several RCTs 
and observational studies (Scavuzzi et al 2013, Heikinheimo et al 2010, Edelman et al 2011, 
Espey et al 2014, Ibrahim et al 2013). Importantly, this option could also be used for difficult 
IUC extractions.  
When priming with misoprostol prior to surgical abortion, the most up-to-date gold standard 
has been 400 mcg misoprostol vaginally or sublingually three hours prior to surgery (Hamoda 
2004). Since most surgical abortions are performed as day-care surgery, many women (in 
Sweden) take the misoprostol tablets at home to reach this priming interval. Some women 
will start bleeding and risk expulsion before reaching the clinic. In study IV we compared 
sublingual to vaginal misoprostol, with priming interval of one or three hours. In accordance 
with study I, we could show efficacy of sublingual priming already after one hour, while 
vaginal priming needs a longer interval to reach the same efficacy. Importantly, we had as 
good a priming effect after one hour sublingual priming as after three hours vaginal or 
sublingual priming, both when comparing cervical baseline dilatation, peak force and 
cumulative force needed to enter the cervical os (study IV).  A clear correlation between 
baseline dilatation and cumulative force was also found.  Both parameters are interesting, 
since the force needed to dilate the cervix has been proven to correlate to surgical 
complications and damage to the cervix and uterus (Hulka et al 1974), and the degree of 
cervical dilatation and cervical trauma has been associated with cervical insufficiency in 
future pregnancies (Berkowitz et al 1981, Martius et al 1998). Although it is known that all 
women benefit from misoprostol priming prior to vacuum aspiration (Meirik et al 2012), and 
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that it is our clinical routine to treat all, we chose to enrol only nulliparous women in the 
study to ensure comparability concerning cervical baseline dilatation. Ideally only 
primigravida women would have been recruited to reduce variation even more. 
Significantly fewer women started bleeding prior to vacuum aspiration when sublingual 
priming time was reduced to one hour. Women treated with sublingual misoprostol had 
significantly more shivering and diarrhoea compared with the untreated group in study I. As 
expected, there was also a slightly lower rate of side-effects in the vaginal treatment groups 
compared with the sublingual groups in study IV. However, in our study, only abdominal 
pain reached significance, and was lower in the vaginal one hour priming group, 
corresponding to the lower priming efficacy in this group. In patients where nausea and 
vomiting makes sublingual treatment difficult, this knowledge could be used for choosing the 
vaginal route of administration instead. If the vaginal route is chosen the priming interval 
should be increased to three hours to reach equal efficacy. Priming intervals beyond three 
hours or using higher doses than 400 mcg of misoprostol results in more side effects but does 
not increase efficacy (Fiala et al 2007).  
It has often been concluded that women prefer the oral or sublingual route of administration 
to the vaginal (Ho et al 1997, Ngai et al 2000, Tang et al 2002, Arvidsson et al 2005). Studies 
have also found that members of  staff prefer oral administration, to “avoid vaginal 
examination” (Hamoda et al 2004). In study IV, there was an overwhelming majority 
preferring the vaginal route. Most women stated the long time for the tablets to dissolve and 
taste of the tablets as reasons (study IV). The women were also allowed to administer the 
tablets themselves, which is an important factor for the acceptability of the vaginal route. 
There might be an advantage of offering different administration routes, particularly if there 
is a problem with nausea, or if there is a shortage of time.  Some of the disadvantages with 
sublingual administration could also be addressed, in developing a designed misoprostol 
product for this use.  
 
5.3 MIFEPRISTONE AND MISOPROSTOL IN BREAST MILK 
5.3.1 Misoprostol 
Nursing mothers may need misoprostol for several reasons. When there is an unmet need for 
contraception, under-use of LARC and when  contraception is too late after childbirth, 
women may resort to abortion to space childbirths. Generally, long-acting reversible 
contraception (LARC) is under-used, and women may be advised to delay initiation of 
LARC, or are prescribed less effective methods such as progesterone-only pills after delivery.  
In Finland up to 10 % of induced abortion patients are nursing mothers (Heikinheimo, 
personal communications 2010, www.stakes.fi/FI/). There are also cases where misoprostol 
could be administered in case of postpartum haemorrhage, endometritis, or suspected 
placental remainants after delivery. There are theoretical advantages of using misoprostol  for 
these indications as well instead of the old-fashioned drugs such as ergometrine and 
prostaglandin F2 alpha. IUC insertion can be more difficult during the breastfeeding period, 
and the risk of perforation is higher for this group (Kaislasuo et al 2012). Misoprostol could 
be used to facilitate the insertion through a narrow cervix, instead of forceful dilatation.  
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There have been reports about periostal changes in infants treated with high doses of 
intravenous prostaglandin for cardiovascular indications (Ringel et al 1983), however, no 
such case is reported after misoprostol use during labour, in the post-partum period or during 
breast-feeding. The transfer of a drug into breast-milk depends on molecular size, 
hydrophilic/lipofilic nature and the degree of protein binding (Berlin and Briggs 2005, 
Anderson 2006).Since the active substance is misoprostol acid, and acidic drugs favour 
ionization in the slightly more alkaline plasma (pH7.4), compared with the slightly more 
acidic breast milk (pH7.1), there will be less transport into breast-milk, and also a reverse 
transportation back to maternal plasma. In general, milk:plasma ratios of acidic drugs will 
therefore be <1.0 (Berlin and Briggs 2005). Also, misoprostol acid is 80-90% bound to serum 
protein. Plasma-concentration of misoprostol acid in breast-milk reaches only 0.04 (0.001-
0.198) after 30 minutes and 0.06 (0.02-0.16) after one hour after oral misoprostol (Vogel et al 
2004). It has been concluded, that the effects of misoprostol in breast-milk on the term infant 
or the under one year-infant, should be negligible and self-limiting, consisting mainly of 
gastrointestinal side-effects.  
5.3.2 Mifepristone 
Data have been lacking concerning the transfer of mifepristone into human breast milk. The 
transfer of mifepristone may be proportionally higher with a higher dose, since mifepristone 
strongly binds to human α1-acid glycoprotein in plasma (Sitruk-Ware and Spitz 2003), and 
the transfer occurs mainly of the free circulating mifepristone and metabolites, which 
increases after the protein-binding capacity is saturated. From this point of view, lowering the 
dose of mifepristone to 200 mg, thus reducing the proportion of free circulating mifepristone 
in plasma, increases safety margins during lactation. Given the long half-life of mifepristone 
of 20-40 hours, there is a potential effect on the foetus due to the antagonstic effect on the 
glucocortiocoid receptor. From studies on foetuses from second-trimester abortion, it has 
been shown that mifepristone can alter the steroid concentrations and elevate the aldosterone 
levels in the foetus, but there is no evidence of teratogenic effect in on-going pregnancies 
after exposure during the first trimester (Hill et al 1990, Bernard et al 2013). The low transfer 
of mifepristone into human breast milk was proven in our study (study II), with milk:serum 
ratios ranging from <0.013(detection limit):1 to 0.042:1.The relative infant dose (RID) will 
be 0.5% when calculated from the highest detected concentration, multiplied with the highest 
daily milk intake in a fully breast-fed infant (Wallgren 1945). As values of around 1% are 
generally considered safe (Berlin and Briggs 2005, Andersson 2006), all restrictions of 
medical abortion and continuing breastfeeding should be abolished.  
 
5.4 IUC AND POST ABORTION CONTRACEPTION (STUDY I AND III). 
Studies have shown that many women, including those who are young and nulliparous, 
choose a long-acting contraceptive method when they are able to choose freely (Secura et al 
2014), and the LNG-IUS has been shown to have a higher continuation rate than oral 
contraceptives in nulliparous women (Suhonen et al 2004). There is no difference in efficacy 
between women of different ages and parity concerning IUC. In contrast to IUC  oral 
contraceptive pills, the patch and the contraceptive vaginal ring  have significantly higher 
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failure rates, which are also magnified in young women (Mc Nicholas and Peipert 2012). It is 
therefore important to improve information about the high efficacy and safety, and to 
improve contraceptive counselling concerning IUC. Apart from the highly effective 
contraceptive function of the LNG-IUS, and the various positive effects on limiting menstrual 
blood loss and dysmenorrhoea, there are also environmental benefits, both in regard of less 
hormonal waste compared with oral contraceptives, as well as decreased need for sanitary 
products due to the profound decrease in bleeding among users. In areas where there is a high 
burden of diseases such as malaria, sickle cell anaemia and high prevalence of uterine 
leiomyoma among the female population, the beneficial impact of Mirena® is difficult to 
overestimate.   
In study I and III, we found a high acceptability for the IUC method among the nulliparous 
women in accordance with previous studies. In study I, only one woman out of 80 nulliparous 
women interrupted the insertion procedure, and 79% said they were willing to go though the 
procedure again. Since menorrhagia is less common in young women – there could be a 
higher acceptance for the Cu-IUD in this group. IUC and particularly LNG-IUS is currently 
underused in the young nulliparous group of women, and facilitating access and insertion has 
a potential in regard to reducing the number of unplanned pregnancies as well as repeat 
abortion (Gemzell Danielsson et al 2013, Cameron 2012). 
Long-acting reversible contraception (LARC) is shown to reduce the risk of repeat abortions 
as well as unplanned pregnancies in comparison with other contraceptive methods (Cameron 
2012).  Following an induced abortion, many women feel motivated to try a contraceptive 
method. There are however great differences between the modern contraceptives in efficacy 
to reduce the risk of a repeat abortion. Intrauterine contraception has been proven to be highly 
effective to prevent a repeat abortion, with higher efficacy than oral contraceptives or any 
other non-IUC (Cameron 2012, Mc Nicholas and Peipert 2012, Heikinheimo et al 2008).  
In comparison with surgical abortion, it has been a disadvantage of the medical method, that 
the IUC cannot be inserted immediately. This is also a disadvantage regarding home-
abortion. However, as shown in study III (Sääv et al 2012) early IUC insertion after first 
trimester medical abortion was not associated with any increased risk of expulsion, infection, 
bleeding or pain when compared with routine inserting. Importantly, the delayed, routine 
insertion will in 83% of women occur after the first ovulation (Lähteenmäki and Luukkainen 
1978).  One reason for the low expulsion rate in the study could be that all IUC were 
confirmed to be in situ by ultrasound post insertion, thus no insertions should have been sub-
optimal with the IUC in the cervix. Expulsion has been proven to be slightly higher when 
insertion takes place immediately after a surgical abortion, however when looking at IUC use 
6 months post abortion, it is significantly higher in the group that receives the IUC 
immediately post abortion (Gillett et al 1980, Grimes et al 2010). It is now recommended, 
that IUC can be inserted as soon as the possibility of ongoing pregnancy or missed abortion 
has been ruled out, and does not carry a higher risk of PID than delayed insertion, and with 
low rates of expulsion (WHO Clinical practice handbook for Safe abortion 2014, Betstadt et 
al 2011, Shimoni et al 2011, Sääv et al 2012). Expulsion rate and safety also needs to be 
further investigated to define the best care  after second trimester abortion, as it is of 
particular interest to avoid (sub-standard) surgical second trimester abortions.   
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In study III it was shown that women were significantly more likely to show up for insertion 
of an IUC, when scheduled early. Also, a substantial number of women had resumed 
intercourse before the IUC insertion both when scheduled early (16%) and according to 
routine (41%), with the important difference that the women undergoing early insertion had 
the IUC inserted before return of ovulation.  Improving access and fast implementation of 
LARC is important after medical abortion to reduce the number of repeat abortions, but also 
to help women avoid a surgical abortion which they may not otherwise choose. It is an 
important advantage to offer IUC insertion early after first trimester medical abortion, which 
is the abortion method of choice for the majority of women (Winikoff 1995, Fiala and 
Gemzell Danielsson 2006). This is particularly important in settings where surgical care 
might not be performed with safe, modern methods. Also, WHO states, that second trimester 
abortion should be performed medically, where there is substandard care for surgical abortion 
and where trained operators are lacking (WHO Clinical practice handbook for Safe abortion 
2014). It is also likely that an increasing number of women will choose home-abortion and 
the possibility of self-diagnosing complete abortion, and those women must be given the 
opportunity to initiate LARC promptly after the abortion. 
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6 CONCLUSIONS 
 
6.1.1 Misoprostol for cervical priming in (Study I and IV)  
Misoprostol reduces the cervical resistance, and can be used to facilitate insertion of an IUC 
and decrease the risk of difficult or failed insertions. Sublingual administration of misoprostol 
with a priming interval of one hour was proven effective, both for cervical priming prior to 
insertion of an IUC, and for cervical dilatation prior to surgical abortion.  Sublingual priming 
with misoprostol was proven to be as effective after one hour as after three hours priming 
interval in regard to baseline cervical dilatation, peak force and cumulative force, and was 
more effective compared with vaginal administration when priming interval was reduced to 
one hour.  
Reducing the priming interval to one hour when misoprostol is administered sublingually 
reduces the number of women who start bleeding prior to surgical abortion. Also, patients can 
be treated at admittance to the clinic and avoid bleeding and expulsion before reaching the 
clinic. More patients reported chills and shivering after sublingual misoprostol priming 
compared with controls. Fewer women reported abdominal pain one hour after vaginal 
misoprostol priming, corresponding to the difference in priming efficacy. There was no 
difference in duration of surgery or amount of bleeding between vaginal and sublingual 
groups regardless of priming interval. The majority of women preferred vaginal treatment to 
sublingual, most frequently due to the taste of the misoprostol tablets.  
 
6.1.2 Levels of mifepristone in human breast milk in women undergoing 
medical abortion (study II) 
Levels of mifepristone in breast milk after medical abortion were low, and in some cases 
even un-detectable after a single dose of 200 mg mifepristone. Milk:serum ratio ranged from 
<0.013:1 to 0.042:1 on day three. The relative infant dose was calculated to 0.5%. Medical 
abortion can be the method of choice also for nursing mothers, and breastfeeding can be 
safely continued in an uninterrupted manner. 
 
6.1.3 IUC and post abortion contraception (Study I and III) 
The incidence of expulsion after IUC insertion during the first week after medical abortion up 
to 9 weeks (9+0) was not increased compared with delayed insertion, and could not be 
predicted by the ultrasound examination. There was no increased risk of pelvic infections, 
perforations or heavy bleeding after early insertion after medical abortion. The LNG-IUS 
reduced the number of days with heavy bleeding after medical abortion compared with Cu-
IUD. More women were motivated to return for IUC insertion when scheduled early. IUC 
use after 6 months was similar after early and delayed insertion. Early insertion should 
therefore be offered as a routine after medical abortion, to ensure fast initiation of 
contraception (LARC). There is a high acceptability of IUC also among nulliparous women. 
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Misoprostol improved the ease of insertion and did not increase the pain associated with the 
placement, however it did not reduce pain during IUC insertion, and carries side-effects such 
as shivering and diarrhoea. Therefore the use should be restricted to a subset of women with 
expected difficult insertion or after a failed attempt. 
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6.2 CLINICAL RECOMMENDATIONS 
 
Misoprostol prior to IUC insertion 
 Priming with misoprostol is usually not necessary, even in nulliparous women. It can 
be recommended if difficult insertion can be anticipated, i.e. after long use of depo-
provera or implants, after previous difficult insertions or failed attempts.  
 A single dose of 400 mcg misoprostol can be given either sublingually one hour prior 
to insertion. For this indication other routes of administration or intervals remain to be 
studied.  
 
Medical abortion in lactating women 
 Medical abortion can be the method of choice also for nursing mothers. 
 Lactation should continue in an uninterrupted manner during medical abortion. 
 
IUC after medical abortion 
 IUC can be safely inserted as soon as an ongoing pregnancy has been ruled out, either 
by performing an ultrasound examination or by a semi-quantified s-hcg test 
 Endometrial diameter does not correlate to the risk of IUC expulsion 
 Women should be scheduled early for IUC insertion, immediately after expulsion of 
the gestational sac, or during the first week, to ensure fast initiation of IUC as 
 women will be more likely to return for IUC insertion if scheduled shortly after the 
abortion 
 
Priming with misoprostol prior to surgical abortion 
 All women undergoing mechanical dilatation prior to vacuum aspiration should 
receive medical priming with 400 mcg misoprostol 
 Misoprostol can be administered sublingually one hour prior to surgery (for example 
at admittance to the clinic) 
 The priming interval should be reduced to one hour when misoprostol is administered 
sublingually to reduce side effects 
 If vaginal administration of misoprostol is preferred, priming interval should be three 
hours. 
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6.3 POSSIBLE AREAS FOR FUTURE RESEARCH 
 
 Development of designated misoprostol product for sublingual and vaginal 
administration 
 Further studies on post abortion contraception (PAC), especially in low-income 
settings 
 Second trimester abortion – safety, acceptability and ways of implementation 
compared with D&E 
 IUC insertion early after 2nd trimester abortion; timing and evaluation of safety. 
 IUC insertion after childbirth: Why should it not be feasible to insert an IUC between 
48 hours and 4 weeks postpartum?  
 Evaluate misoprostol for indications where patients today are treated with old-
fashioned drugs, such as ergometrine and prostaglandin F2 Alpha; medical treatment 
of retained placenta, late postpartum bleeding and endometritis. 
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7 FILM RECOMMENDATIONS 
 
For further inspiration, I wish to include a list of films that in different ways bring up abortion related 
issues. (With kind support from Rebecca Gomperts, Women on Web) 
 
Drama: 
Kreuzzug des weibes (1926)  
Valborgsmässoafton(Walpurgis night)  
Malice (Bill Pullman)  
If these walls could talk 
4 Months, 3 Weeks and 2 Days 
Amok (1934 film) 
Apio Verde 
The Banishment 
The Cider House Rules (film) 
Citizen Ruth 
The Crime of Father Amaro 
Decalogue II 
Devil Returns 
Dirty Dancing 
The Group (film) 
Hinugot sa Langit 
If These Walls Could Talk 
The Marriage of Maria Braun 
My Body, My Child 
Obvious Child 
October Baby 
Ordet 
País do Desejo 
Palindromes 
Polyester 
A Private Matter 
Rain Without Thunder 
Sarah's Choice 
The Scarlet Worm 
A Simple Story (1978 film) 
Stato interessante 
Story of Women 
Street Corner (1948 film) 
Sulang Kirilli 
Swing Vote (1999 film) 
Under the Pavement Lies the Strand 
Vera Drake 
 
Documentaries: 
The Abortion Pill  
After Tiller 
Eclipse of Reason 
The Fragile Promise of Choice: Abortion in the 
United States Today 
From Danger to Dignity: The Fight for Safe 
Abortion 
Lake of Fire (film) 
Live Free or Die (2000 film) 
Maafa 21 
Motherhood by Choice, Not Chance 
Vessel (film) 
What's the Matter with Kansas?  
When Abortion Was Illegal: Untold Stories 
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